Serial No.: 09/943,138

Applicant: Wallace K. DYER


Filed: August 30, 2001

Title: Methods and Compositions for Tissue Augmentation

Page: 2

## CLEAN COPY OF AMENDMENTS

## In the Claims:



- (Amended) A biphasic injectable composition comprising:
   solid polymer particles, wherein the solid polymer particles are mechanically
   stable and are suspended in a liquid carrier substrate.
- 2. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles are made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.
- 3. (Amended) The composition of Claim 1, wherein the mechanically stable solid polymer particles are made from at least two of micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

ATLLIB02 22985.1

1 1

Serial No.: 09/943,138 Applicant: Wallace K. DYER

Filed: August 30, 2001

Title: Methods and Compositions for Tissue Augmentation

Page: 3

- (Amended) The composition of Claim 1, wherein the liquid carrier substrate phase is selected from polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.
- (Amended) The composition of Claim 1, wherein the mechanically 5. stable solid polymer particles comprise micronized expanded polytetrafluoroethelene ("e-PTFE") particles.
- (Amended) The composition of Claim 1, wherein the liquid carrier 7. substrate phase is polyvinylpyrrolidone.
- of Claim 7, wherein composition (Amended) The 8. polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.
- wherein composition of Claim 7. (Amended) The 9. polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.
- Claim 7, wherein composition of The (Amended) 10. polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.
- wherein Claim 7, composition of (Amended) The 11. polyvinylpyrrolidone comprises a K value of 17.
- (Amended) The composition of Claim 1, wherein the mechanically 12. stable solid polymer particles comprise e-PTFE; and

the carrier substrate comprises polyvinylpyrrolidone.

ATLL1802 22985.1

1 1

Serial No.: 09/943,138

Applicant: Wallace K. DYER

Filed: August 30, 2001

Title: Methods and Compositions for Tissue Augmentation

Page: 4

- 13. (Amended) The composition of Claim 12 wherein the e-PTFE and the PVP are combined at a ratio of approximately 3:2 polyvinylpyrrolidone to e-PTFE by weight.
- 14. (Amended) The composition of Claim I, wherein the mechanically stable solid polymer particles comprise micronized polydioxanone particles ranging in size from approximately 65 to 1000 micrometers.
- 15. (Amended) A method for tissue augmentation comprising:
  injecting a biphasic injectable composition comprising:
  solid polymer particles wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.
- 16. (Amended) The method of Claim 15, wherein the mechanically stable solid polymer particles are made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.
- 17. (Amended) The method of Claim 15, wherein the liquid carrier substrate **MIMM** is selected from polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.



ATLLIDO2 22985.1